Trials / Not Yet Recruiting

Not Yet RecruitingNCT07346547

REDCURE Registry for Chronic Kidney Disease (CKD) Anemia

Registry of Daprodustat in Chronic Kidney Disease (CKD) Anemia for Understanding Real-World Evidence (REDCURE)

Status: Not Yet Recruiting
Phase: —
Study type: Observational
Enrollment: 384 (estimated)

Sponsor: Nabiqasim Industries (Pvt) Ltd · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

A local registry on CKD-associated anemia aims to provide real-world insights into disease burden, treatment patterns, and outcomes at the national level. It helps capture variations in anemia severity with CKD stages, therapeutic practices and their response. It also supports evidence-based decision-making, identifies gaps in care, and informs locally relevant guidelines and policy planning to improve patient outcomes with oral novel therapy i.e. daprodustat

Conditions

CKD Anemia

Interventions

Type	Name	Description
DRUG	Daprodustat	Hypoxia Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor (PHI) drug

Timeline

Start date: 2026-01-30
Primary completion: 2027-01-30
Completion: 2027-05-31
First posted: 2026-01-16
Last updated: 2026-01-20

Source: ClinicalTrials.gov record NCT07346547. Inclusion in this directory is not an endorsement.